Cutaneous Hyperpigmentation Secondary to High-Dose Tigecycline: A Case Report

High-dose tigecycline therapy is gaining wide acceptance in treating infections caused by multidrug-resistant bacteria. There are no reports of cutaneous hyperpigmentation with the use of high-dose tigecycline. Here we report a case of a woman who developed reversible cutaneous hyperpigmentation wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsemari, Muhannad A., Hakeam, Hakeam A., Alsalman, Hussain, Amin, Tarek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453436/
https://www.ncbi.nlm.nih.gov/pubmed/32922782
http://dx.doi.org/10.1177/2049936120952605
_version_ 1783575353700122624
author Alsemari, Muhannad A.
Hakeam, Hakeam A.
Alsalman, Hussain
Amin, Tarek
author_facet Alsemari, Muhannad A.
Hakeam, Hakeam A.
Alsalman, Hussain
Amin, Tarek
author_sort Alsemari, Muhannad A.
collection PubMed
description High-dose tigecycline therapy is gaining wide acceptance in treating infections caused by multidrug-resistant bacteria. There are no reports of cutaneous hyperpigmentation with the use of high-dose tigecycline. Here we report a case of a woman who developed reversible cutaneous hyperpigmentation within 48 h of receiving high-dose tigecycline.
format Online
Article
Text
id pubmed-7453436
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-74534362020-09-11 Cutaneous Hyperpigmentation Secondary to High-Dose Tigecycline: A Case Report Alsemari, Muhannad A. Hakeam, Hakeam A. Alsalman, Hussain Amin, Tarek Ther Adv Infect Dis Case Report High-dose tigecycline therapy is gaining wide acceptance in treating infections caused by multidrug-resistant bacteria. There are no reports of cutaneous hyperpigmentation with the use of high-dose tigecycline. Here we report a case of a woman who developed reversible cutaneous hyperpigmentation within 48 h of receiving high-dose tigecycline. SAGE Publications 2020-08-26 /pmc/articles/PMC7453436/ /pubmed/32922782 http://dx.doi.org/10.1177/2049936120952605 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Alsemari, Muhannad A.
Hakeam, Hakeam A.
Alsalman, Hussain
Amin, Tarek
Cutaneous Hyperpigmentation Secondary to High-Dose Tigecycline: A Case Report
title Cutaneous Hyperpigmentation Secondary to High-Dose Tigecycline: A Case Report
title_full Cutaneous Hyperpigmentation Secondary to High-Dose Tigecycline: A Case Report
title_fullStr Cutaneous Hyperpigmentation Secondary to High-Dose Tigecycline: A Case Report
title_full_unstemmed Cutaneous Hyperpigmentation Secondary to High-Dose Tigecycline: A Case Report
title_short Cutaneous Hyperpigmentation Secondary to High-Dose Tigecycline: A Case Report
title_sort cutaneous hyperpigmentation secondary to high-dose tigecycline: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453436/
https://www.ncbi.nlm.nih.gov/pubmed/32922782
http://dx.doi.org/10.1177/2049936120952605
work_keys_str_mv AT alsemarimuhannada cutaneoushyperpigmentationsecondarytohighdosetigecyclineacasereport
AT hakeamhakeama cutaneoushyperpigmentationsecondarytohighdosetigecyclineacasereport
AT alsalmanhussain cutaneoushyperpigmentationsecondarytohighdosetigecyclineacasereport
AT amintarek cutaneoushyperpigmentationsecondarytohighdosetigecyclineacasereport

Ejemplares similares